Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGENFree Report) in a research note published on Monday. The brokerage issued a sell rating on the stock.

Oragenics Stock Performance

OGEN opened at $0.28 on Monday. The stock’s 50 day moving average price is $0.32 and its 200-day moving average price is $0.46. Oragenics has a one year low of $0.25 and a one year high of $3.43. The stock has a market cap of $3.42 million, a price-to-earnings ratio of -0.04 and a beta of 0.38.

Oragenics Company Profile

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

See Also

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.